Immunohistochemical stainings demonstrated positivity for p-mTOR in 14/23 Lynch syndrome tumors and in 12/23 sporadic tumors (p = 0.767), positive staining for EGFR in 7/23 Lynch tumors and in 2/22 sporadic tumors (p = 0.135) and loss of PTEN in 17/23 Lynch syndrome tumors compared to in 14/23 sporadic tumors (p = 0.530) (Fig. 4). The gene discussed is EGFR; the disease is Lynch syndrome.